- Real-time information integration connects hospital, manufacturing, and logistics for a streamlined supply process
- ERP-linked automation of production and shipment schedules ensures operational efficiency and precision
[by Ji, Yong Jun] Curocell announced on July 21 the successful development of ‘CUROLINK,’ an integrated solution designed to track and manage the entire process from prescription to administration in real time. This system has been established in preparation for the upcoming commercialization of ‘RIMQARTO,’ a next-generation chimeric antigen receptor T cell (CAR-T) therapy.
CUROLINK is a cloud-based cell therapy supply management solution developed under an official license from Salesforce, the world’s No. 1 customer relationship management (CRM) platform provider. Over the course of approximately two years, the system was developed in phases and structured to align with hospital workflow, incorporating feedback from actual clinical sites. According to the company, CUROLINK is seamlessly integrated with existing hospital systems, enabling real-time information sharing among hospitals, manufacturing facilities, and logistics providers, thereby increasing usability and on-site adoption.
CUROLINK is also integrated with Curocell’s enterprise resource planning (ERP) system, enabling automatic coordination of the entire supply chain, including production planning, material management, schedule reservations, and shipment tracking, with patient treatment timelines. This integration facilitates the automation of manufacturing inputs and batch management for time-sensitive cell therapy products, thereby minimizing operational risks such as resource overlap or shipment delays.
In addition, CUROLINK ensures data consistency across departments such as accounting, quality control, and logistics, while automatically generating and managing approval documents and administrative procedures related to shipment, thereby significantly enhancing operational efficiency across the organization. The company emphasized that CUROLINK enables end-to-end tracking of the entire process, from product ordering to leukapheresis, cell manufacturing, shipment, and administration, through an integrated system. This is achieved by integrating and managing patient-level information between the hospital’s component collection room, pharmaceutical team, GMP manufacturing facility, and logistics providers.
The system has now been stabilized and validated, and 바카라 온라인 is set to be introduced sequentially at major Korean hospitals in line with the launch of RIMQARTO. Curocell plans to position 바카라 온라인 as a core digital asset and actively deploy it throughout the entire therapeutic supply system in the future.
“CUROLINK is an integrated solution that fundamentally transforms the operational framework for the commercialization of CAR-T treatments,” said Kim Gun-soo, CEO of Curocell. “By improving the precision of treatment scheduling and the efficiency of the supply process, it is expected to play a pivotal role in the future expansion of treatment indications and the global supply chain,” he added.